Aquestive Therapeutics (AQST) announced a $75M strategic funding agreement with funds managed by RTW Investments, subject to United States FDA approval of Anaphylm Sublingual Film and other conditions. “This financing provides critical capital that will support Aquestive Therapeutics through 2027, enabling us to successfully bring Anaphylm to market, if approved by the FDA, and deliver a new treatment option for patients in need,” said Dan Barber, Chief Executive Officer of Aquestive. “We continue to believe Anaphylm, potentially the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis, can transform how patients carry and access their rescue medication. We are excited to partner with RTW to bring this important medication to patients, if approved by the FDA.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Aquestive Therapeutics Reports Q2 2025 Financial Results
- AQST Earnings this Week: How Will it Perform?
- Aquestive Therapeutics Faces Potential Risks with ‘5050Item’: What Investors Need to Know
- Aquestive Therapeutics promotes Korczynski to Chief Commercial Officer
- Aquestive Therapeutics provides international expansion update for Anaphylm